Free Trial

Abbott Laboratories (ABT) Stock Price, News & Analysis

-1.91 (-1.84%)
(As of 07/8/2024 ET)
Today's Range
50-Day Range
52-Week Range
4.54 million shs
Average Volume
5.65 million shs
Market Capitalization
$177.63 billion
P/E Ratio
Dividend Yield
Price Target

Abbott Laboratories MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
17.7% Upside
$120.18 Price Target
Short Interest
0.67% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.91mentions of Abbott Laboratories in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$3.48 M Sold Last Quarter
Proj. Earnings Growth
From $4.62 to $5.12 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.99 out of 5 stars

Medical Sector

4th out of 876 stocks

Pharmaceutical Preparations Industry

1st out of 416 stocks

ABT stock logo

About Abbott Laboratories Stock (NYSE:ABT)

Abbott Laboratories is a global healthcare company specializing in developing, manufacturing and marketing a wide range of healthcare products. The company has its headquarters in Abbott Park, Illinois and operates in more than 160 countries worldwide.

The company was founded in 1888 by Dr. Wallace C. Abbott, and it has since grown to become one of the world's largest and most respected healthcare companies. Abbott Laboratories has a diverse portfolio of products, including medical devices, diagnostic tests, nutritional products, and branded generic pharmaceuticals. The company is committed to developing innovative products that improve the quality of life for people worldwide.

Robert B. Ford is the current President and CEO of the company. He was appointed to this position in 2020 after serving as the company's Chief Operating Officer. He has been with Abbott Laboratories since 1996 and has held various leadership positions.

Abbott Laboratories has delivered strong financial performance, declining as investors seek growth. The company's net earnings have been increasing steadily. Abbott Laboratories has a solid balance sheet with a low debt-to-equity ratio. The company has consistently delivered strong cash flow, allowing it to invest in research and development and return value to shareholders. Abbott Laboratories has a higher price-to-earnings ratio than the industry average, and the company's price-to-book ratio is also higher than the industry average. These metrics suggest that the market has a positive outlook on Abbott Laboratories and is willing to pay a premium for the company's shares. Over the past year, Abbott Laboratories' stock has declined as consumers seek to see what the company will do post-pandemic. The company's shares have experienced some volatility, but overall, they have outperformed the broader market. 

Abbott Laboratories operates in the healthcare industry, which is highly regulated and complex. The industry is characterized by rapidly evolving technology, changing regulatory requirements, and shifting consumer preferences. Abbott Laboratories competes with other large healthcare companies such as Johnson & Johnson.

Abbott Laboratories' robust product pipeline is expected to drive growth in the coming years. The company is focused on developing innovative products that address unmet medical needs and improve patient outcomes. In addition to its core businesses, Abbott Laboratories is expanding into new markets and investing in digital health technologies.

Like any company, Abbott Laboratories faces a range of risks and challenges. One of the most significant risks facing the company is regulatory uncertainty. Changes in regulatory requirements could impact the company's ability to bring products to market and could also increase the cost of doing business. Another risk facing the company is the threat of competitive pressures. The healthcare industry is highly competitive, and Abbott Laboratories faces competition from established companies and new entrants. Changes in consumer preferences could also impact the company's performance, particularly in the nutritional products segment.

Additionally, Abbott Laboratories is exposed to geopolitical risks, such as changes in trade policies or political instability in key markets. The company's international operations also expose it to currency fluctuations, which could impact its financial performance.

ABT Stock Price History

ABT Stock News Headlines

Pharmacist, scientist developing new medicines, medicaments, pharmacy, chemistry
AbbVie Stock: A Perfect Dip for Investors to Buy (ABT)
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors
Young billionaire opens the door for millions of Americans
You can now profit from a catalog of 11 inventions that will likely make their way into millions of U.S. households in the months and years to come. And you can do this whether you’re rich or poor… There are no special income requirements.
The 3 Best Healthcare Stocks to Buy in July 2024
Young billionaire opens the door for millions of Americans
You can now profit from a catalog of 11 inventions that will likely make their way into millions of U.S. households in the months and years to come. And you can do this whether you’re rich or poor… There are no special income requirements.
3 MedTech Stocks to Buy for Healthy Gains
See More Headlines
Receive ABT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 5/15 Dividend
Last Earnings
Dividend Payable
Ex-Dividend for 8/15 Dividend
Next Earnings (Confirmed)
Dividend Payable
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Health Care Equipment
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
$5.72 billion
Pretax Margin


Sales & Book Value

Annual Sales
$40.11 billion
Cash Flow
$6.25 per share
Book Value
$22.36 per share


Outstanding Shares
Free Float
Market Cap
$177.63 billion

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained


Here are some ways that investors could benefit from investing in Abbott Laboratories:

  • Abbott Laboratories has a strong return on equity of 20.18%, indicating efficient use of shareholder funds to generate profits.
  • The company has a healthy dividend payout ratio of 68.54%, providing investors with a steady income stream.
  • Abbott Laboratories has a diversified product portfolio across healthcare segments, reducing risk associated with dependence on a single product line.
  • The company's recent earnings report showed a positive surprise, beating analyst estimates by $0.02 per share, reflecting strong operational performance.
  • With a debt-to-equity ratio of 0.32, Abbott Laboratories maintains a conservative capital structure, reducing financial risk for investors.


Investors should be bearish about investing in Abbott Laboratories for these reasons:

  • Abbott Laboratories faces competition in the healthcare industry, which could impact its market share and profitability.
  • The company's stock price may be influenced by regulatory changes in the healthcare sector, leading to volatility in the stock value.
  • Market analysts have revised price targets for Abbott Laboratories, indicating uncertainty in future growth prospects.
  • Abbott Laboratories operates in a highly regulated industry, subject to stringent compliance requirements that could affect operational flexibility.
  • Investors should closely monitor macroeconomic factors that could impact healthcare spending and demand for Abbott Laboratories' products.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these Abbott Laboratories pros and cons to

ABT Stock Analysis - Frequently Asked Questions

How have ABT shares performed this year?

Abbott Laboratories' stock was trading at $110.07 at the start of the year. Since then, ABT stock has decreased by 7.2% and is now trading at $102.11.
View the best growth stocks for 2024 here

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) issued its quarterly earnings results on Wednesday, April, 17th. The healthcare product maker reported $0.98 earnings per share for the quarter, beating analysts' consensus estimates of $0.96 by $0.02. Abbott Laboratories's revenue for the quarter was up 2.2% on a year-over-year basis.
Read the conference call transcript

What is Robert Ford's approval rating as Abbott Laboratories' CEO?

183 employees have rated Abbott Laboratories Chief Executive Officer Robert Ford on Robert Ford has an approval rating of 89% among the company's employees.

Does Abbott Laboratories have any subsidiaries?

Abbott Laboratories subsidiaries include Cephea Valve Technologies, Alere, St. Jude Medical, Kalila Medical, Tendyne Holdings Inc., Veropharm, Topera Inc., and others.

Who are Abbott Laboratories' major shareholders?

Top institutional shareholders of Abbott Laboratories include DNB Asset Management AS (0.03%), Woodstock Corp (0.01%), First Financial Bank Trust Division (0.01%) and Beese Fulmer Investment Management Inc. (0.01%). Insiders that own company stock include Daniel J Starks, Jr Robert E Funck, Jr Robert E Funck, Robert B Ford, Daniel Gesua Sive Salvadori, John F Ginascol, Andrea F Wainer, Lisa D Earnhardt, Joseph J Manning, Randel William Woodgrift, Julie L Tyler, John A Jr Mccoy, Fernando Mateus, Nancy Mckinstry, Mary K Moreland, Louis H Morrone, Sammy Karam, Michael J Pederson, Michael D Dale, Andrew H Lane and Philip P Boudreau.
View institutional ownership trends

How do I buy shares of Abbott Laboratories?

Shares of ABT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Abbott Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Abbott Laboratories investors own include AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T), Pfizer (PFE), Walt Disney (DIS) and Cisco Systems (CSCO).

This page (NYSE:ABT) was last updated on 7/9/2024 by Staff

From Our Partners